Literature DB >> 29434335

Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.

David T Teachey1, Michael R Bishop2, David G Maloney3, Stephan A Grupp1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29434335     DOI： 10.1038/nrclinonc.2018.19

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  15 in total

1.  Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

Authors:  Cameron J Turtle; Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; Sindhu Cherian; Xueyan Chen; Brent Wood; Arletta Lozanski; John C Byrd; Shelly Heimfeld; Stanley R Riddell; David G Maloney
Journal:  J Clin Oncol       Date:  2017-07-17       Impact factor: 44.544

2.  Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.

Authors:  Julie C Fitzgerald; Scott L Weiss; Shannon L Maude; David M Barrett; Simon F Lacey; J Joseph Melenhorst; Pamela Shaw; Robert A Berg; Carl H June; David L Porter; Noelle V Frey; Stephan A Grupp; David T Teachey
Journal:  Crit Care Med       Date:  2017-02       Impact factor: 7.598

3.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Authors:  Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall
Journal:  Lancet       Date:  2014-10-13       Impact factor: 79.321

4.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

Review 5.  Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Authors:  Sattva S Neelapu; Sudhakar Tummala; Partow Kebriaei; William Wierda; Cristina Gutierrez; Frederick L Locke; Krishna V Komanduri; Yi Lin; Nitin Jain; Naval Daver; Jason Westin; Alison M Gulbis; Monica E Loghin; John F de Groot; Sherry Adkins; Suzanne E Davis; Katayoun Rezvani; Patrick Hwu; Elizabeth J Shpall
Journal:  Nat Rev Clin Oncol       Date:  2017-09-19       Impact factor: 66.675

6.  Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003.

Authors:  Rachael Hough; Clare Rowntree; Nick Goulden; Chris Mitchell; Anthony Moorman; Rachel Wade; Ajay Vora
Journal:  Br J Haematol       Date:  2015-12-18       Impact factor: 6.998

7.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

8.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.

Authors:  David L Porter; Wei-Ting Hwang; Noelle V Frey; Simon F Lacey; Pamela A Shaw; Alison W Loren; Adam Bagg; Katherine T Marcucci; Angela Shen; Vanessa Gonzalez; David Ambrose; Stephan A Grupp; Anne Chew; Zhaohui Zheng; Michael C Milone; Bruce L Levine; Jan J Melenhorst; Carl H June
Journal:  Sci Transl Med       Date:  2015-09-02       Impact factor: 17.956

9.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

Review 10.  How to Treat Involvement of the Central Nervous System in Hemophagocytic Lymphohistiocytosis?

Authors:  AnnaCarin Horne; Ronny Wickström; Michael B Jordan; E Ann Yeh; Ahmed Naqvi; Jan-Inge Henter; Gritta Janka
Journal:  Curr Treat Options Neurol       Date:  2017-01       Impact factor: 3.598
View more
  30 in total

1.  Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial.

Authors:  Jeremy S Abramson; Tanya Siddiqi; Jacob Garcia; Christine Dehner; Yeonhee Kim; Andy Nguyen; Sophie Snyder; November McGarvey; Matthew Gitlin; Corey Pelletier; Monika P Jun
Journal:  Blood Adv       Date:  2021-03-23

Review 2.  Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities.

Authors:  Rajshekhar Chakraborty; Surbhi Sidana; Gunjan L Shah; Michael Scordo; Betty K Hamilton; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-28       Impact factor: 5.742

Review 3.  Cellular therapy: Immune-related complications.

Authors:  Joseph H Oved; David M Barrett; David T Teachey
Journal:  Immunol Rev       Date:  2019-07       Impact factor: 12.988

4.  An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.

Authors:  Jialing Zhang; Stephan S Späth; Sherman M Weissman; Samuel G Katz
Journal:  Methods Mol Biol       Date:  2020

5.  Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma.

Authors:  Talha Badar; Bryon D Johnson; Mehdi Hamadani
Journal:  Bone Marrow Transplant       Date:  2020-08-11       Impact factor: 5.483

6.  Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.

Authors:  Sattva S Neelapu; Sudhakar Tummala; Partow Kebriaei; William Wierda; Frederick L Locke; Yi Lin; Nitin Jain; Naval Daver; Alison M Gulbis; Sherry Adkins; Katayoun Rezvani; Patrick Hwu; Elizabeth J Shpall
Journal:  Nat Rev Clin Oncol       Date:  2018-02-13       Impact factor: 66.675

7.  A Growing Problem of Critical Illness Due to Chimeric Antigen Receptor T-Cell Therapy.

Authors:  Dusan Hanidziar; Edward Bittner
Journal:  Crit Care Med       Date:  2018-11       Impact factor: 7.598

8.  Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation.

Authors:  Jingsheng Hua; Jian Zhang; Xinyou Zhang; Xiaoxia Wu; Lili Zhou; Xiebing Bao; Yue Han; Miao Miao; Caixia Li; Chengcheng Fu; Suning Chen; Xiaowen Tang; Depei Wu; Huiying Qiu
Journal:  Bone Marrow Transplant       Date:  2020-11-24       Impact factor: 5.483

Review 9.  Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.

Authors:  Jennifer N Brudno; James N Kochenderfer
Journal:  Blood Rev       Date:  2018-11-14       Impact factor: 8.250

Review 10.  Current development of chimeric antigen receptor T-cell therapy.

Authors:  Jiasheng Wang; Yongxian Hu; He Huang
Journal:  Stem Cell Investig       Date:  2018-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.